Lipophilic drugs and toxins

Lipophilic drugs and toxins represent a physicochemical classification of substances rather than a specific biological target. These compounds are characterized by their high solubility in non-polar solvents and a high octanol-water partition coefficient (logP) (Source: PubChem, NIH). Because they are not a single molecular entity, they do not have a singular biological function; instead, they are defined by their ability to passively diffuse across lipid bilayers and sequester in adipose tissue (Source: StatPearls, 'Pharmacokinetics'). Many lipophilic substances serve as ligands for nuclear receptors such as the Pregnane X Receptor (PXR) and the Constitutive Androstane Receptor (CAR), which coordinate the transcriptional up-regulation of metabolic enzymes like Cytochrome P450 to facilitate detoxification (Source: PubMed, PMID: 12130547). Their lipophilicity is a major determinant of drug distribution, often leading to a high volume of distribution and the ability to cross the blood-brain barrier (Source: Wikipedia, 'Lipophilicity'). Consequently, these substances pose unique safety challenges, including the risk of bioaccumulation and prolonged toxicity due to slow release from fat stores (Source: NIH, 'ToxTutor'). In drug development, managing lipophilicity is essential to balance potency with favorable pharmacokinetic properties and safety profiles.

Other names

Lipophilic xenobioticsHydrophobic compoundsFat-soluble substancesLipid-soluble drugs

Lipophilic drugs and toxins typically interact with biological systems through passive diffusion across lipid bilayers and by acting as substrates or ligands for metabolic enzymes and nuclear receptors.